Perscription Drug User Fee Act Reauthorization
FDA funding and agency effectiveness
Drug importation issues
Safeguarding America's Pharmaceuticals Act of 2011- H.R. 3026
Issues relating to Medicare Part D rebates
FDA funding and agency effectiveness
Potential Super Committee legislation affecting Medciare Part D and Medicaid rebates
Issues related to prevention, diagnosis and treatment of diabetes
Duration: June 1, 2006
to
August 31, 2012
General Issues: Pharmacy , Medicare/Medicaid , Budget/Appropriations , Health Issues , Copyright/Patent/Trademark , Medical/Disease Research/Clinical Labs , Veterans , Taxation/Internal Revenue Code
Spending: about $5,653,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2006: House of Representatives, U.S. Senate, Food & Drug Administration (FDA), U.S. Senate,, Health & Human Services - Dept of (HHS), Executive Office of the President (EOP), Commerce - Dept of (DOC), Centers For Medicare and Medicaid Services (CMS)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Craig Burton
Dep. Asst. Sec. for Legislation- HHS (04-08)
Staff, Senate HELP Cmte (1998-04)
Staff, Senator Bill Frist (1998-04)
Staff, Senate HELP (1998-04)
Dep. Asst. Sec.for Legislation- HHS (04-08)
Dep. Assistant Sec. for Legislation, HHS (04-08)
Staff, Senate HELP Committee (1998-2004)
Staff, Senator Bill Frist (1998-2004)
Depty. Asst. Sec. for Legislation-HHS (04-08)
Staff, Senate HELP Cmte. (1998-04)
Dep. Asst. Sec. for Legislation (04-08)
Staff, Senator Bill Frist, (1998-04)
Sharon Yeske-Amato
n/a
William Franco
n/a
Mercedes Barrs
n/a
Meredes Barrs
n/a
PETER NORMAN
n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
3rd Quarter, 2012
AMYLIN PHARMACEUTICALS in-house lobbying effort was terminated on Sept. 19, 2012
Original Filing: 300502817.xml
Lobbying Issues
Perscription Drug User Fee Act Reauthorization
FDA funding and agency effectiveness
Drug importation issues
Safeguarding America's Pharmaceuticals Act of 2011- H.R. 3026
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues relating to Medicare Part D rebates
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
FDA funding and agency effectiveness
Potential Super Committee legislation affecting Medciare Part D and Medicaid rebates
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to prevention, diagnosis and treatment of diabetes
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2012
In Q2, AMYLIN PHARMACEUTICALS had in-house lobbyists. The report was filed on July 19, 2012.
Original Filing: 300492157.xml
Lobbying Issues
Perscription Drug User Fee Act Reauthorization
FDA funding and agency effectiveness
Drug importation issues
Safeguarding America's Pharmaceuticals Act of 2011- H.R. 3026
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues relating to Medicare Part D rebates
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
FDA funding and agency effectiveness
Potential Super Committee legislation affecting Medciare Part D and Medicaid rebates
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to prevention, diagnosis and treatment of diabetes
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2012
In Q1, AMYLIN PHARMACEUTICALS had in-house lobbyists. The report was filed on April 20, 2012.
Original Filing: 300470151.xml
Lobbying Issues
Perscription Drug User Fee Act Reauthorization
FDA funding and agency effectiveness
Drug importation issues
Safeguarding America's Pharmaceuticals Act of 2011- H.R. 3026
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues relating to Medicare Part D rebates
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
FDA funding and agency effectiveness
Potential Super Committee legislation affecting Medciare Part D and Medicaid rebates
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to prevention, diagnosis and treatment of diabetes
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2011
In Q4, AMYLIN PHARMACEUTICALS had in-house lobbyists. The report was filed on Jan. 20, 2012.
Original Filing: 300451241.xml
Lobbying Issues
Perscription Drug User Fee Act Reauthorization
FDA funding and agency effectiveness
Drug importation issues
Safeguarding America's Pharmaceuticals Act of 2011- H.R. 3026
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues relating to Medicare Part D rebates
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
FDA funding and agency effectiveness
Potential Super Committee legislation affecting Medciare Part D and Medicaid rebates
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to prevention, diagnosis and treatment of diabetes
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2011
In Q3, AMYLIN PHARMACEUTICALS had in-house lobbyists. The report was filed on Oct. 20, 2011.
Original Filing: 300427070.xml
Lobbying Issues
Perscription Drug User Fee Act reauthorization
FDA funding and agency effectiveness
Drug importation issues
Safeguarding America's Pharmaceuticals Act of 2011- H.R. 3026
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues relating to Medicare Part D rebates
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to the America Invents Act (S. 23, H.R. 1249)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
FDA funding and agency effectiveness
Potential Super Committee legislation affecting Medciare Part D and Medicaid rebates
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to prevention, diagnosis and treatment of diabetes
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2011
In Q2, AMYLIN PHARMACEUTICALS had in-house lobbyists. The report was filed on July 19, 2011.
Original Filing: 300397253.xml
Lobbying Issues
Perscription Drug User Fee Act reauthorization
FDA funding and agency effectiveness
Drug importation issues
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Provisions related to comparative effectiveness research in HR 3590 Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Provisions related to the expansion of Medicaid rebates in Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Provisions related to the expansion of Medicaid eligibility in Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Provisions related to Medicare Part D rebates Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Medicare and Medicaid provisions of H.R. 4213, American Jobs and Closing Tax Loopholes Act of 2010
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Exclusivity, damages,estoppel, post grant review and inter partes review provisions in the America Invents Act (S. 23, H.R. 1249)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
FDA funding and agency effectiveness
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Prevention, diagnosis and treatment of diabetes
Diabetes issues related to implementation of provisions of Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2011
In Q1, AMYLIN PHARMACEUTICALS had in-house lobbyists. The report was filed on April 20, 2011.
Original Filing: 300375930.xml
Lobbying Issues
Perscription Drug User Fee Act reauthorization
FDA funding and agency effectiveness
Drug importation issues
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Exclusivity, damages, estoppel, post grant review and inter partes review provisions in the America Invents Act (S. 23, H.R. 1249)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
FDA funding and agency effectiveness
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Prevention, diagnosis and treatment of diabetes
Diabetes issues related to implementation of provisions of Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2010
In Q4, AMYLIN PHARMACEUTICALS had in-house lobbyists. The report was filed on Jan. 20, 2011.
Original Filing: 300349106.xml
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Provisions related to comparative effectiveness research in HR 3590 Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Provisions related to the expansion of Medicaid rebates in Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Provisions related to the expansion of Medicaid eligibility in Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Provisions related to Medicare Part D rebates Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Medicare and Medicaid provisions of H.R. 4213, American Jobs and Closing Tax Loopholes Act of 2010
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Exclusivity, damages and estoppel provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Comparative effectiveness research and reimbursement in Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Prescription drug issues
Chronic disease and diabetes treatment issues within the Veterans Administration
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Health care reform issues in H.R. 4872 Health Care Education and Reconciliation Act of 2010 related to Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2010
In Q3, AMYLIN PHARMACEUTICALS had in-house lobbyists. The report was filed on Oct. 19, 2010.
Original Filing: 300317792.xml
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Provisions related to comparative effectiveness research in HR 3590 Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Provisions related to the expansion of Medicaid rebates in Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Provisions related to the expansion of Medicaid eligibility in Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Provisions related to Medicare Part D rebates Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Medicare and Medicaid provisions of H.R. 4213, American Jobs and Closing Tax Loopholes Act of 2010
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Exclusivity, damages and estoppel provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Comparative effectiveness research and reimbursement in Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Prescription drug issues
Chronic disease and diabetes treatment issues within the Veterans Administration
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Health care reform issues in H.R. 4872 Health Care Education and Reconciliation Act of 2010 related to Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2010
In Q2, AMYLIN PHARMACEUTICALS had in-house lobbyists. The report was filed on July 19, 2010.
Original Filing: 300294147.xml
Lobbying Issues
Physician Payments Sunshine provision of Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
FDA Risk Evaulation Mitigation Strategies (REMS)
Drug Safety Communications
Drug importation issues
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Provisions related to comparative effectiveness research in HR 3590 Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Provisions related to the expansion of Medicaid rebates in Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Provisions related to the expansion of Medicaid eligibility in Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Provisions related to Medicare Part D rebates Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Medicare and Medicaid provisions of H.R. 4213, American Jobs and Closing Tax Loopholes Act of 2010
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Exclusivity, damages and estoppel provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Chronic disease and diabetes care related provisions in Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Provisions related to comparative effectiveness reserach and reimbursement in Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Prescription drug issues
Chronic disease and diabetes treatment issues within the Veterans Administration
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Health care reform issues in H.R. 4872 Health Care Education and Reconciliation Act of 2010 related to Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2010
In Q1, AMYLIN PHARMACEUTICALS had in-house lobbyists. The report was filed on April 19, 2010.
Original Filing: 300266244.xml
Lobbying Issues
Physician Payments Sunshine provision of HR 3590 the Patient Protection and Affordable Care Act and H.R.4872 the Health Care and Education Reconciliation Act of 2010
FDA Risk Evaulation Mitigation Strategies (REMS)
Drug Safety CommunicationsDrug importation issues in HR 3590 the Patient Protection and Affordable Care Act and H.R.4872 the Health Care and Education Reconciliation Act of 2010
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Provisions related to comparative effectiveness research in HR 3590 the Patient Protection and Affordable Care Act and H.R.4872 the Health Care and Education Reconciliation Act of 2010
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Provisions related to the expansion of Medicaid rebates in HR 3590 the Patient Protection and Affordable Care Act and H.R.4872 the Health Care and Education Reconciliation Act of 2010
Provisions related to the expansion of Medicaid eligibility in HR 3590 the Patient Protection and Affordable Care Act and H.R.4872 the Health Care and Education Reconciliation Act of 2010
Provisions related to Medicare Part D rebates in HR 3590 the Patient Protection and Affordable Care Act and H.R.4872 the Health Care and Education Reconciliation Act of 2010
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Exclusivity, damages and estoppel provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Chronic disease and diabetes care related provisions in HR 3590 the Patient Protection and Affordable Care Act and H.R.4872 the Health Care and Education Reconciliation Act of 2010
Provisions related to comparative effectiveness reserach and reimbursement HR 3590 the Patient Protection and Affordable Care Act and H.R.4872 the Health Care and Education Reconciliation Act of 2010
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2009
In Q4, AMYLIN PHARMACEUTICALS had in-house lobbyists. The report was filed on Jan. 15, 2010.
Original Filing: 300232893.xml
Lobbying Issues
Physician Payments Sunshine provision of H.R. 3200 America's Affordable Health Choices Act of 2009
Physician Payments Sunshine provision of Affordable Health Care for America Act (H.R. 3962)- House
Physician Payments Sunshine provision of Patient Protection and Affordable Care Act (H.R. 3590)-Senate
FDA Risk Evaulation Mitigation Strategies (REMS)Drug Safety Communications
Drug importation issues in the Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA)
Lobbying Issues
Provisions related to comparative effectiveness reserach in the Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Provisions related to the expansion of Medicaid rebates in the Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate
Provisions related to the expansion of Medicaid eligibility in the Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-SenateProvisions related to Medicare Part D in the Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Exclusivity, damanges and estoppel provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Comparative effectiveness provisions in the American Recovery and Reinvestment Act (H.R. 1)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Chronic disease and diabetes care related provisions in Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate
Provisions related to comparative effectiveness reserach and reimbursement in the Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2009
AMYLIN PHARMACEUTICALS amended a lobbying report for in-house lobbying in Q32009 on Jan. 15, 2010
Original Filing: 300232887.xml
Lobbying Issues
Data exclusivity provisions in H.R. 1548, Pathway for Biosimilars Act
Data eclsuivity provisions in Promoting Innovation and Access to Life-Saving Medicine Act (H.R. 1427,S. 726)
Physician Payments Sunshine provision of H.R. 3200 America's Affordable Health Choices Act of 2009
FDA Risk Evaulation Mitigation Strategies (REMS)Drug Safety Communications
Drug importation issues
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA)
Lobbying Issues
Comparative Effectiveness Research Act of 2009 (H.R. 2502)
Patient Centered Outcomes research Act of 2009 (S. 1213)
Provisions related to comparative effectiveness reserach in S. 1679, the Affordable Health Choices Act; H.R. 3200 America's Affordable Health Choices Act of 2009; America's Healthy Futures Act of 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare provisions and Medicaid rebate issues in S. 1679, the Affordable Health Choices Act; America's Healthy Futures
Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
H.R. 2502 Comparative Effectiveness Research Act of 2009
S. 1213 Patient Centered Outcomes Research Act of 2009Provisions related to comparative effectiveness reserach and reimbursement in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Lobbying Issues
Exclusivity, and damanges provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Comparative effectiveness provisions in the American Recovery and Reinvestment Act (H.R. 1)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Chronic disease and diabetes care related provisions in S. 1679, the Affordable Health Choices Act; America's Healthy Futures
Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
H.R. 2502 Comparative Effectiveness Research Act of 2009
S. 1213 Patient Centered Outcomes Research Act of 2009Provisions related to comparative effectiveness reserach and reimbursement in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2009
In Q3, AMYLIN PHARMACEUTICALS had in-house lobbyists. The report was filed on Oct. 16, 2009.
Original Filing: 300207345.xml
Lobbying Issues
Data exclusivity provisions in H.R. 1548, Pathway for Biosimilars Act
Data eclsuivity provisions in Promoting Innovation and Access to Life-Saving Medicine Act (H.R. 1427,S. 726)
Physician Payments Sunshine provision of H.R. 3200 America's Affordable Health Choices Act of 2009
FDA Risk Evaulation Mitigation Strategies (REMS)Drug Safety Communications
Drug importation issues
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA)
Lobbying Issues
Comparative Effectiveness Research Act of 2009 (H.R. 2502)
Patient Centered Outcomes research Act of 2009 (S. 1213)
Provisions related to comparative effectiveness reserach in S. 1679, the Affordable Health Choices Act; H.R. 3200 America's Affordable Health Choices Act of 2009; America's Healthy Futures Act of 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare provisions and Medicaid rebate issues in S. 1679, the Affordable Health Choices Act; America's Healthy Futures
Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
H.R. 2502 Comparative Effectiveness Research Act of 2009
S. 1213 Patient Centered Outcomes Research Act of 2009Provisions related to comparative effectiveness reserach and reimbursement in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Lobbying Issues
Exclusivity, and damanges provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Comparative effectiveness provisions in the American Recovery and Reinvestment Act (H.R. 1)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Chronic disease and diabetes care related provisions in S. 1679, the Affordable Health Choices Act; America's Healthy Futures
Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
H.R. 2502 Comparative Effectiveness Research Act of 2009
S. 1213 Patient Centered Outcomes Research Act of 2009Provisions related to comparative effectiveness reserach and reimbursement in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2009
In Q2, AMYLIN PHARMACEUTICALS had in-house lobbyists. The report was filed on July 17, 2009.
Original Filing: 300182106.xml
Lobbying Issues
Payment disclsoure regulations in the Physician Payments Sunshine Act of 2009
Data exclusivity provisions in H.R. 1548, Pathway for Biosimilars Act
Data eclsuivity provisions in Promoting Innovation and Access to Life-Saving Medicine Act (H.R. 1427,S. 726)
Regulatory provisions in the Food and Drug Administration Globalization Act of 2009 (H.R. 759)Drug Importation/Drug Safety
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
Lobbying Issues
Provisions relating to diabetes research and comparative effectiveness in the Labor Health Human Services Appropriations FY 2010 (no bill number)
Comparative Effectiveness Research Act of 2009 (H.R. 2502)
Patient Centered Outcomes research Act of 2009 (S. 1213)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare Issues
Reimbursement issues in Medicare Payment Advisory Commisssion (MedPAC) Reform Act of 2009 (S.1110)
Medicare provisions and Medicaid rebate issues in the Affordable Health Choices Act (Senate), Americas Affordable Health Choices Act (H.R. 3200), Senate Finance Healthcare Reform Bill, Tri Caucus Healthcare Reform BillH.R. 2502 Comparative Effectiveness Research Act of 2009
S. 1213 Patient Centered Outcomes Research Act of 2009- Comparative Effectiveness
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Exclusivity, and damanges provisions in the Patent reform Act of 2009 (S. 515, H.R. 1260)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Comparative effectiveness provisions in the American Recovery and Reinvestment Act (H.R. 1)
S. Con. Res. 13, H. Con. Res. 85
Provisions relating to diabetes research and comparative effectiveness in the Labor Health Human Services Appropriations FY 2010
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Reimbursement issues in the Medicare Payment Advisory Commisssion (MedPAC) Reform Act of 2009 (S.1110)
Chronic disease and diabetes care related provisions of the Affordable Health Choices Act (Senate), Americas Affordable Health Choices Act (H.R. 3200), Senate Finance Healthcare Reform Bill and Tri Caucus Healthcare Reform Bill
H.R. 2502 Comparative Effectiveness Research Act of 2009S. 1213 Patient Centered Outcomes research Act of 2009- Comparative Effectiveness
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2009
In Q1, AMYLIN PHARMACEUTICALS had in-house lobbyists. The report was filed on April 17, 2009.
Original Filing: 300154718.xml
Lobbying Issues
S. 301, Physician Payments Sunshine Act of 2009
H.R. 1548, Pathway for Biosimilars Act
H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act
S. 726, Promoting Innovation and Access to Life-Saving Medicine ActDrug Importation/Drug Safety
H.R. 759, Food and Drug Administration Globalization Act of 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
Lobbying Issues
S. 515, Patent reform Act of 2009
S. 610, Patent Reform Act of 2009
H.R. 1260, Patent Reform Act of 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Type of Issue
Copyright/Patent/Trademark
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Labor Health Human Services Appropriations FY 2010 (no bill number)-provisions relating to Diabetes Research and Comparative Effectiveness
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
H.R.1, American Recovery and Reinvestment Act
S. Con. Res. 13
H. Con. Res. 85
FY10 Budget
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2008
In Q4, AMYLIN PHARMACEUTICALS had in-house lobbyists. The report was filed on Jan. 17, 2009.
Original Filing: 300125469.xml
Lobbying Issues
H.R.1038, Access to Life-Saving Medicine Act, follow-on biologics
H.R.1561, Enhancing Drug Safety and Innovation Act of 2007
H.R.1956, Patient Protection and Innovative Biologics Medicines Act of 2007, follow-on biologics
S.1505, Affordable Biologics for Consumers Act, follow-on biologicsS.1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics
S. 2029, Physician Payments Sunshine Act of 2007
S.596, Safe Internet Pharmacy Act of 2007
S. 623, Acces to Life-Saving Medicine Act, follow-on biologics
H.R.5629, Pathway for Biosimilars Act
H.R.5839, Safeguarding America's Pharmaceuticals Act
Drug Imporation
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS) Executive Office of the President (EOP)
Lobbying Issues
S.1145, Patent Reform Act of 2007, entire bill
H.R.1908, Patent Reform Act of 2007, entire bill
S. 3600, Patent Reform Act of 2008, entire bill
Agencies Lobbied
U.S. House of Representatives U.S. Senate Commerce - Dept of (DOC) Executive Office of the President (EOP)
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H.R.5480, Medicare Funding Warning Response Act of 2008
H.R.2602, 340B Program Improvement and Integrity Act of 2007, 340B drug price expansion
H.R.4, Medicare Prescription Drug Price Negotiation Act, Medicare "non-interference" provisions
S. 3, Medicare Prescription Drug Price Negotiation Act, Medicare "non-interference" provisionsS.1376, 340B Program Improvement and Integrity Act of 2007, 340B drug price expansion
S.2029, Physician Payments Sunshine Act of 2007
S.2662, Medicare Funding Warning Response Act of 2007
H.R.1424, Emergency Economic Stabalization Act of 2008
H.R.3162, Childrens Health and Medicare Protection Act of 2007
SCHIP (Senate), Medicare cuts to finance SCHIP expansion
S. 3101, Medicare Improvements for Patients and Providers Act of 2008
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
FY09 Administration Budget
House Concurrent Resolution 312 FY09 Revised Congressional Budget
Senate Concurrent Resolution 70 FY09 Congresssional Budget
Comparative EffectivenessFDA/ Drug Importation
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Comparative Effectiveness
LHHS Appropriations
Diabetes Research Issues
H.R. 2638, Consolidated Security, Disaster Assistance, and Continuing Appropriations Act of 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Extension of the R&D Tax Credit
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2008
In Q3, AMYLIN PHARMACEUTICALS had in-house lobbyists. The report was filed on Oct. 17, 2008.
Original Filing: 300098998.xml
Lobbying Issues
H.R.1038, Access to Life-Saving Medicine Act, follow-on biologics
H.R.1561, Enhancing Drug Safety and Innovation Act of 2007
H.R.1956, Patient Protection and Innovative Biologics Medicines Act of 2007, follow-on biologics
S.1505, Affordable Biologics for Consumers Act, follow-on biologicsS.1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics
S. 2029, Physician Payments Sunshine Act of 2007
S.596, Safe Internet Pharmacy Act of 2007
S. 623, Acces to Life-Saving Medicine Act, follow-on biologics
H.R.5629, Pathway for Biosimilars Act
H.R.5839, Safeguarding America's Pharmaceuticals Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS) Executive Office of the President (EOP)
Lobbying Issues
S.1145, Patent Reform Act of 2007, entire bill
H.R.1908, Patent Reform Act of 2007, entire bill
Agencies Lobbied
U.S. House of Representatives U.S. Senate Commerce - Dept of (DOC) Executive Office of the President (EOP)
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H.R.5480, Medicare Funding Warning Response Act of 2008
H.R.2606, 340B Program Improvement and Integrity Act of 2007, 340B drug price expansion
H.R.4, Medicare Prescription Drug Price Negotiation Act, Medicare "non-interference" provisions
H.R.3162, Childrens Health and Medicare Protection Act of 2007S.1376, 340B Program Improvement and Integrity Act of 2007, 340B drug price expansion
S.2029, Physician Payments Sunshine Act of 2007
S.2662, Medicare Funding Warning Response Act of 2007
H.R.1424, Emergency Economic Stabalization Act of 2008
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
FY09 Administration Budget
House Concurrent Resolution 312 FY09 Revised Congressional Budget
Senate Concurrent Resolution 70 FY09 Congresssional Budget
Comparative EffectivenessFDA/ Drug Importation
H.R. 2638, Consolidated Security, Disaster Assistance, and Continuing Appropriations Act of 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Comparative Effectiveness
LHHS Appropriations
Diabetes Research Issues
H.R. 2638, Consolidated Security, Disaster Assistance, and Continuing Appropriations Act of 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Extension of the R&D Tax Credit
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2008
In Q2, AMYLIN PHARMACEUTICALS had in-house lobbyists. The report was filed on July 17, 2008.
Original Filing: 300068704.xml
Lobbying Issues
H.R. 1038, Access to Life-Saving Medicine Act, follow-on biologics
H.R. 1561, Enhancing Drug Safety and Innovation Act of 2007, drug safety provisions
H.R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, follow-on biologics
S. 1505, Affordable Biologics for Consumers Act, follow-on biologicsS. 1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics
S. 2029, Physician Payments Sunshine Act of 2007
S. 596 Safe Internet Pharmacy Act of 2007, clinical trials, drug safety provisions
S. 623, Access to Life-Saving Medicine Act, follow-on biologics
Drug Importation
H.R., Pathway for Biosimilars Act
H.R. 5839, Safeguarding America's Pharmaceuticals Act of 2008
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS) Executive Office of the President (EOP)
Lobbying Issues
S. 1145, Patent reform Act of 2007, entire bill
H.R. 1908, Patent Reform Act of 2007, entire bill
Agencies Lobbied
U.S. House of Representatives U.S. Senate Commerce - Dept of (DOC) Executive Office of the President (EOP)
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H.R. 2606, 340B Program Improvement and Integrity Act of 2007, 340B drug price expansion
H.R. 3162, Children's Health and Medicare Protection Act of 2007
H.R. 4, Medicare Prescription Drug Price Negotiation Act, Medicare "non-interference" provisions
H.R. 5480, Medicare Funding Warning Response Act of 2008S. 1376, 340B Program Improvement and Integrity Act of 2007, 340B drug price expansion
S. 2029, Physician Payments Sunshine Act of 2007
S. 2662, Medicare Funding Warning Response Act of 2008
S. 3, Medicare Prescription Drug Price Negotiation Act, Medicare "non-interference" provisions
SCHIP (Senate), Medicare cuts to finance SCHIP expansion
H.R., Medicare Improvements for Patients and Providers Act of 2008
S. 3101, Medicare Improvements for Patients and Providers Act of 2008
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Comparative Effectiveness
FY09 Administration Budget
House Concurrent Resolution 312, FY09 Revised Congressional Budget
Senate Concurrent Resolution 70, FY09 Congressional BudgetFDA/drug importation
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
LHHS Appropriations
Diabetes Research Issues
Comparative Effectiveness
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Extension of the R&D Tax Credit
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2008
In Q1, AMYLIN PHARMACEUTICALS had in-house lobbyists. The report was filed on April 16, 2008.
Original Filing: 300038982.xml
Lobbying Issues
HR 1038, Access to Life-Saving Medicines Act, follow-on biologics
HR 1561, Enhancing Drug Safety and Innovation Act of 2007
HR 1956, Patient Protection and Innovative Biologics Medicines Act of 2007, follow-on biologics
S. 1505, Affordable Biologics for Consumers Act, follow-on biologicsS. 1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics
S. 2029, Physician Payments Sunshine Act of 2007
S. 596, Safe Internet Pharmacy Act of 2007, clinical trials/drug safety provisions
S. 623, Access to Life Saving Medicine Act, follow-on biologics
Drug Importation
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS) Food & Drug Administration (FDA) Executive Office of the President (EOP)
Lobbying Issues
Comparative Effectiveness
Diabetes research issues
LHHS appropriations
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
HR 2606, 340B Program Improvement and Intergrity Act, 340B drug price expansion
HR 3162, Children Health and Medicare Protection Act of 2007
HR 4, Medicare Precription Drug Price Negotiation Act, Medicare "non-interference" provisions
HR 5480, Medicare Funding Warning Response of 2008S. 1376, 340B Program Improvement and Integrity Act of 2007, 340B drug price expansion
S. 2029, Physician Payments Sunshine Act of 2007
S. 2662, Medicare Funding Warning Response Act of 2008
S. 3, Medicare Prescription Drug Price Negotiation Act, Medicare "non-interference" provisions
SCHIP (Senate), Medicare cuts to finance SCHIP expansion
Agencies Lobbied
U.S. House of Representatives U.S. House of Representatives
Lobbying Issues
S. 1145, Patent Reform Act of 2007, entire bill
HR 1908, Patent Reform Act of 2007, entire bill
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
FY09 Adminstration Budget
House Concurrent Resolution 312 FY09 Revised Congressional Budget
Senate Concurrent Resolution 70 FY09 Congresisonal Budget
Comparative EffectivenessFDA/drug importation
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate